Five-year outcome in 18 010 patients from the German Aortic Valve Registry.


Journal

European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
ISSN: 1873-734X
Titre abrégé: Eur J Cardiothorac Surg
Pays: Germany
ID NLM: 8804069

Informations de publication

Date de publication:
02 11 2021
Historique:
received: 29 12 2020
revised: 17 03 2021
accepted: 24 03 2021
pubmed: 5 5 2021
medline: 15 12 2021
entrez: 4 5 2021
Statut: ppublish

Résumé

To determine the 5-year outcome in patients treated by isolated transcatheter aortic valve implantation (TAVI) or surgical aortic valve replacement (sAVR)-a prospective observational cohort study. A total of 18 010 patients were included (n = 8942 TAVI and n = 9068 sAVR) in the German Aortic Valve Registry (GARY) who were treated in 2011 and 2012 at 92 sites in central Germany. Eligible patients with TAVI and sAVR were matched using propensity scores in a nearest-neighbour approach. Patients with repeat procedures or unequivocal indication for one treatment option (e.g. frailty) were excluded (n = 4785 for TAVI and n = 2 for sAVR). This led to 13 223 patients (4157 TAVI and 9066 sAVR) as an unmatched subcohort. The main outcome measure was the 5-year all-cause mortality. TAVI patients were significantly older (80.9 ± 6.1 vs 68.5 ± 11.1 years, P < 0.001), had a higher Society of Thoracic Surgeons (STS) score (6.3 ± 4.9 vs 2.6 ± 3.0, P < 0.001) and a higher 5-year all-cause mortality (49.8% vs 16.5%, P < 0.0001). There was no major difference in in-hospital stroke, in-hospital myocardial infarction, or temporary and chronic dialysis. In the propensity score-matched group (n = 3640), there were 763 deaths (41.9%) among 1820 TAVI patients compared with 552 (30.3%) among 1820 treated with sAVR during the 5-year follow-up (hazard ratio 1.51, 95% confidence interval 1.35-1.68; P < 0.0001). New pacemaker implantation was performed in 448 patients (24.6%) after TAVI and in 201 (11.0%) after sAVR (P < 0.0001). The 5-year follow-up data show that TAVI patients were significantly older and had a higher STS score than sAVR patients. After propensity score matching, TAVI with early-generation prosthesis was associated with significantly higher 5-year all-cause mortality than sAVR.

Identifiants

pubmed: 33942061
pii: 6263469
doi: 10.1093/ejcts/ezab216
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1139-1146

Commentaires et corrections

Type : CommentIn

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Auteurs

Friedhelm Beyersdorf (F)

Department of Cardiovascular Surgery, University Heart Center Freiburg-Bad Krozingen, Freiburg, Germany.
Medical Faculty of the Albert-Ludwigs-University Freiburg, Freiburg, Germany.

Timm Bauer (T)

Department of Cardiology, Sana Klinikum Offenbach, Offenbach, Germany.

Nick Freemantle (N)

Comprehensive Clinical Trial Unit, University College London, London, UK.

Thomas Walther (T)

Department of Thoracic, Cardiac and Thoracic Vascular Surgery, University of Frankfurt, Frankfurt, Germany.

Christian Frerker (C)

Department of Cardiology, University Hospital Cologne, University of Cologne, Faculty of Medicine, Cologne, Germany.

Eva Herrmann (E)

German Center for Cardiovascular Research (DZHK), Partner Site Rhein/Main, Germany.
Institute of Biostatistics and Mathematical Modelling, Goethe University Frankfurt, Frankfurt, Germany.

Sabine Bleiziffer (S)

Department of Thoracic and Cardiovascular Surgery, Heart and Diabetes Center NRW, Bad Oeynhausen, Germany.

Helge Möllmann (H)

Department of Internal Medicine I, St.-Johannes-Hospital, Dortmund, Germany.

Sandra Landwehr (S)

BQS Institute for Quality and Patient Safety, Düsseldorf, Germany.

Stephan Ensminger (S)

Department of Cardiac Surgery, University Hospital Lübeck, Lübeck, Germany.

Raffi Bekeredjian (R)

Department of Cardiology, Robert-Bosch-Hospital, Stuttgart, Germany.

Jochen Cremer (J)

Department of Cardiac and Vascular Surgery, University Hospital Kiel, Kiel, Germany.

Karl Heinz Kuck (KH)

Department of Cardiology, Angiology, Intensive Care, University Hospital Lübeck, Lübeck, Germany.

Buntaro Fujita (B)

Department of Cardiac Surgery, University Hospital Lübeck, Lübeck, Germany.

Jan Gummert (J)

Department of Thoracic and Cardiovascular Surgery, Heart and Diabetes Center NRW, Bad Oeynhausen, Germany.

Lisa Müller (L)

BQS Institute for Quality and Patient Safety, Düsseldorf, Germany.

Andreas Beckmann (A)

Germany Society for Thoracic and Cardiovascular Surgery, Berlin, Germany.

Christian W Hamm (CW)

Department of Cardiology, Campus Kerckhoff University of Giessen, Bad Nauheim, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH